ArticleOncotarget2017
New tumor suppressor microRNAs target glypican-3 in human liver cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Non-coding RNAs participate in interactions between senescence and gastrointestinal cancers.Frontiers in genetics · 2024Pooled it
- Insights into the mechanisms of microRNAs in hepatoblastoma: from diagnosis to treatment.Precision clinical medicine · 2025Review
- A novel ferroptosis-related microRNAs signature for predicting prognosis in endometrial cancer: An observational study.Medicine · 2025Observational
- Characterization of an Activated Metabolic Transcriptional Program in Hepatoblastoma Tumor Cells Using scRNA-seq.International journal of molecular sciences · 2024Article
- The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential.European journal of medical research · 2024Review
- The preliminary data of gene expressions and bioinformatics analysis of miR-146b-5p and miR-4510 in the Turkish population in HBV-related hepatocellular carcinoma.Hepatology forum · 2024Article
- Children's Oncology Group's 2023 blueprint for research: Liver tumors.Pediatric blood & cancer · 2023Article
- Structural and Functional Impact of Posttranslational Modification of Glypican-3 on Liver Carcinogenesis.Cancer research · 2023Review
- Article
- Identification of miR-4510 as a metastasis suppressor of gastric cancer through regulation of tumor microenvironment via targeting GPC3.Clinical & experimental metastasis · 2022Article
- Article
- Deciphering tumour tissue organization by 3D electron microscopy and machine learning.Communications biology · 2021Article
- DUSP9, a Dual-Specificity Phosphatase with a Key Role in Cell Biology and Human Diseases.International journal of molecular sciences · 2021Review
- Article
- Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma.BioMed research international · 2020Review
- MicroRNAs in Animal Models of HCC.Cancers · 2019Review
- Wnt/β-catenin signaling as a useful therapeutic target in hepatoblastoma.Bioscience reports · 2019Review
- The Role of MicroRNAs in Hepatoblastoma Tumors.Cancers · 2019Review
- Diagnostic Value of Glypican-3 for Hepatocellular CarcinomasAsian Pacific journal of cancer prevention : APJCP · 2018Article
- miR-216a-3p Inhibits the Proliferation, Migration, and Invasion of Human Gastric Cancer Cells via Targeting RUNX1 and Activating the NF-κB Signaling Pathway.Oncology research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glypican-3 (GPC3) is an oncogene, frequently upregulated in liver malignancies such as hepatocellular carcinoma (HCC) and hepatoblastoma and constitutes a potential molecular target for therapy in liver cancer. Using a functional screening system, we identified 10 new microRNAs controlling GPC3 expression in malignant liver cells, five of them e.g. miR-4510, miR-203a-3p, miR-548aa, miR-376b-3p and miR-548v reduce GPC3 expression. These 5 microRNAs were significantly downregulated in tumoral compared to non-tumoral liver and inhibited tumor cell proliferation. Interestingly, miR-4510 inversely correlated with GPC3 mRNA and protein in HCC samples. This microRNA also induced apoptosis of hepatoma cells and blocked tumor growth in vivo in the chick chorioallantoic membrane model. We further show that the tumor suppressive effect of miR-4510 is mediated through direct targeting of GPC3 mRNA and inactivation of Wnt/β-catenin transcriptional activity and signaling pathway. Moreover, miR-4510 up-regulated the expression of several tumor suppressor genes while reducing the expression of other pro-oncogenes. In summary, we uncovered several new microRNAs targeting the oncogenic functions of GPC3. We provided strong molecular, cellular and in vivo evidences for the tumor suppressive activities of miR-4510 bringing to the fore the potential value of this microRNA in HCC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.